Edesa Biotech Valeur / Action
Quel est le Valeur / Action de Edesa Biotech?
Le Valeur / Action de Edesa Biotech, Inc. est 1.77
Quelle est la définition de Valeur / Action?
La valeur comptable par action est l'actif de la société moins le passif divisé par le nombre d'actions en circulation.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valeur / Action des entreprises dans Health Care secteur sur NASDAQ par rapport à Edesa Biotech
Que fait Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Entreprises avec valeur / action similaire à Edesa Biotech
- Sky Solar a Valeur / Action de 1.76
- Patriot National Bancorp Inc a Valeur / Action de 1.76
- INmune Bio a Valeur / Action de 1.77
- Extraction Oil & Gas a Valeur / Action de 1.77
- Logic Instrument S.A a Valeur / Action de 1.77
- LINK Mobility ASA a Valeur / Action de 1.77
- Edesa Biotech a Valeur / Action de 1.77
- Lifestyle International a Valeur / Action de 1.77
- Naked Wines plc a Valeur / Action de 1.77
- Dicerna Pharmaceuticals Inc a Valeur / Action de 1.77
- Vulcan Resources a Valeur / Action de 1.77
- Gold Rush Cariboo a Valeur / Action de 1.77
- Westwater Resources Inc a Valeur / Action de 1.77